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20-year follow-up study of Danish HHT
patients—survival and causes of death
Anette Kjeldsen1,2* , Katrine Saldern Aagaard1, Pernille Mathiesen Tørring3, Sören Möller4 and Anders Green4,5
Abstract
Background: Hereditary Haemorrhagic Telangiectasia (HHT) is a dominantly inheritable disorder, with a wide
variety of clinical manifestations due to presence of multiple arteriovenous manifestations. The most common
mutations are found in HHT1 (ENG) and HHT2 (ACVRL1) patients, causing alterations in the TGF-β pathway which is
responsible for angiogenesis. Modulations of angiogenesis may influence cancer rates. The objective of
the study was to evaluate 20-year survival according to HHT subtype, as well as to evaluate differences in causes
of death comparing HHT patients and controls. We also wanted to investigate whether cancer morbidity among
HHT patients differs from that among controls.
Results: We included all HHT patients in the County of Fyn, Denmark, prevalent as of January 1st 1995 in total 73
HHT patients. In addition three age- and sex- matched controls per HHT patient were evaluated, in total 218 controls
(one was lost due to registration failure). The controls were defined at start of follow-up in 1995. Information on lifestyle
factors was not available. A total of 32 (44%) HHT patients and 97 (44%) controls passed away during follow-up. The
survival curves were evenly distributed showing similar survival rates in the two groups. Cancer diagnoses had been
registered in the follow-up period in 4 (5%) HHT patients and in 38 (17%) controls.
Conclusion: The mortality was not increased among Danish HHT patients compared to controls. This study is based on
a clinical unselected series of HHT patients with the whole spectrum of severity, independent of need for medical care.
Our data also suggest that HHT patients to a lesser degree than the background population are affected by cancer.
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Background
Hereditary Hemorrhagic Telangiectasia (HHT), also
known as Osler-Weber-Rendu disease, is an autosomal
dominant disorder characterized by presence of multiple
arteriovenous malformations (AVMs) leading to wide
variety of clinical manifestations [1, 2]. Case reports on
fatal outcome in severe HHT cases have been reported
[3, 4]. However, studies on survival in the overall HHT
population have been sparse [5, 6]. Studies indicate that, at
least in untreated HHT populations, an increased mortality
seems to be present [7]. We have previously studied the
mortality among HHT patients and controls in the county
of Fyn [1, 8], and we identified a slightly increased mortality
in a subgroup of patients. Studies of mortality are
important to be able to advise patients on prognosis, and to
gain information regarding the nature of the disease.
Clinical manifestations of HHT
The most common clinical manifestation of HHT is
spontaneous and recurrent epistaxis, usually with debut
in childhood, ultimately affecting around 95% of all
HHT patients. The epistaxis severity differs considerably
between individual patients. With age HHT patients
develop characteristic red spots (Fig. 1 (telangiectatic
lesions)). Gastrointestinal AVM (GI-AVM) may cause
gastrointestinal bleeding in 25% of HHT patients [2, 9]
who often need blood transfusions. Pulmonary arterio-
venous malformations (PAVMs) are present in around
12–50% depending on the genetic subtype [10–12].
PAVMs may cause serious neurological symptoms like
cerebral abscess (CA) [13–15] or stroke, due to paradox-
ical embolism [10, 16]. Patients with PAVMs are there-
fore recommended treated with embolization, whenever
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possible [17]. Other neurological symptoms may be
caused by cerebral arteriovenous malformations
(CAVMs), which are present in at least 10% of patients
[18]. Hepatic arteriovenous malformations (HAVMs)
are quite common, but rarely symptomatic [2, 19].
Clinical reports show an apparent increased occurrence of
bacterial infection [13–15], and an apparent increased
occurrence of thromboembolic events, and certainly an in-
creased occurrence of non-traumatic haemorrhage [2, 5].
Genetics of HHT
Genetic heterogeneity has been demonstrated with iden-
tification of five loci to date, of which HHT1, HHT2 and
JP-HHT are the most well described. HHT1 is caused by
mutations in Endoglin (ENG) (OMIM 131195) and
HHT2 by mutations in ACVRL1 (Activin A receptor,
type II-like 1) (OMIM 601284). The HHT1 and HHT2
phenotypes share the amount of telangiectatic lesions,
epistaxis and GI bleeding evenly. But HHT1 patients
have a high prevalence of PAVMs while HHT2 have a
higher prevalence of HAVMs. A phenotype consisting of
HHT and Juvenile Polyposis Syndrome (JP-HHT) was
described in 2004 and is due to mutations in SMAD4
(OMIM 600993) [20].
HHT is a clinical diagnosis, according to the Curaçao
criteria [21]. In approximately 85% of the HHT patients
a mutation in either ENG or ACVRL1 can be identified
at mutation analysis, and 2–3% of patients have a muta-
tion in SMAD4 [12].
Cancer and HHT
Mutations in the three HHT causing genes cause alter-
ations in the TGF-β pathway which is responsible for
angiogenesis. Disturbance of angiogenesis causes devel-
opment of telangiectatic lesions, and one may speculate
if disturbances of angiogenesis also alter the occurrence
of cancer. Molecular biology studies have indicated that
at least regarding Endoglin (HHT1) reduced levels may
reflect reduced tumour angiogenesis [22]. In the past
years there have been some indications that HHT
patients may have superior cancer-survival [23] and may
even have a lower risk of cancer [24]. On the other hand,
recently the occurrence of cancer was reported equal to
controls in a large study by Duarte et al. [25].
Epidemiology of HHT
HHT occurs with wide ethnic and geographic distribu-
tion. The reported Danish prevalence is 1/6500 [1]
which is slightly higher compared to other European
countries. However, during the last 20 years increasing
prevalence has been reported from many HHT-center’s
[26, 27]. The higher prevalence is thought to be due to
increased awareness and inclusion of the subset of
patients with minor symptoms rather than truly increas-
ing incidence.
Aim
To estimate survival in our group of HHT patients and
compare the survival with age- and sex-matched
controls.
To see if there are marked differences in causes of
death between the group of HHT patients and in the
group of controls.
To investigate cancer prevalence among HHT patient,
and compare the differences in cancer prevalence
between HHT patients and controls.
Methods
The identification of HHT patients and controls has
been described previously [8, 28]. Basically all known
Fig. 1 Typical telangiectatic lesion in an HHT patient
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HHT patients and all first-degree relatives of HHT
patients living in the County of Fyn were invited for
clinical examination for signs of HHT. Hereby, we iden-
tified all HHT patients who fulfilled the clinical criteria
of HHT, regardless of their need for medical care. A
total of 73 HHT patients who fulfilled the clinical
criteria of HHT 1.1.1995 and lived in the County of Fyn
were included in the follow-up study. The controls
consisted of 218 inhabitants in the County of Fyn the
1.1.1995; they were age- and sex-matched. Three controls
were chosen randomly for each HHT patient when the
HHT cohort was identified in 1995, one control was lost
due to registration failure. As the controls were not con-
tacted and the HHT patients (cases) were only seen at
entry and if they later were in need of medical care at the
HHT-center. Data concerning smoking habits, lifestyle
and comorbidity were not available.
In 2015 we performed a register search in the Danish
Population Registry using the civil registration number
of the HHT cases and of the controls. By this method all
deaths and causes of death among patients and controls
as well as emigrations in the study period were recorded.
Causes of death were retrieved from the Danish Cause
of Death Registry.
In order to further evaluate the causes of death among
patients and controls, a thorough assessment of the
ICD-10 classifications was performed and all diagnoses
were, from a clinical point of view, categorized as HHT-
or not HHT-related. HHT related diagnoses were based
on the reported increased occurrence of bacterial infec-
tions, risk of thromboembolic events, and hemorrhages
among HHT patients [2, 14, 29]. The HHT-related diag-
noses were grouped as seen in Additional files 1: Table
S2. Overview, and Additional files 2: Table S3 including
all diagnosis and all codes.
Regarding cancer, first event of cancer was recorded
both in the HHT group and in the control group. These
data were retrieved from the Danish Patient Registry.
The results where validated by extracting data from the
Danish Cancer Registry. Non-melanoma skin cancers
were omitted from the analysis, as this diagnostic group
are less likely to be complete and accurate.
Setting
The Danish HHT-center was established at Odense Uni-
versity Hospital in 1995 on the basis of several years
with ongoing epidemiological studies in the County of
Fyn [30]. Since 1.1.1995 all patients seen at the Danish
HHT-center have been clinically evaluated concerning
manifestations of HHT. All participants have been
offered genetic testing. The HHT-center receives referral
patients with HHT from all parts of Denmark. However,
concerning the County of Fyn, we have been able to
include and follow all patients from Fyn.
The County of Fyn, Denmark, is a geographical well
defined area with access to Odense University Hospital.
All inhabitants in Denmark are served by a free public
health care system, in which all hospital contacts are
registered. Data concerning prevalence of HHT disease
has previously been published [1, 31].
Clinical evaluation of patients
The HHT patients and their first degree relatives were at
inclusion evaluated regarding symptoms and signs of
HHT. They were interviewed regarding epistaxis and
other HHT manifestations, and they underwent a clin-
ical examination looking for telangiectatic lesions with
focus on characteristic sites, being nasal mucosa, oral
mucosa, lips, skin of face, conjunctiva, and fingertips. In-
cluding the first degree relatives in the HHT screening,
allowed us to identify HHT cases with very few symp-
toms. Only HHT cases with definite HHT were included
in the follow-up. The inclusion criteria at that time were:
presence of multiple, at least 15, telangiectatic lesions
and either a positive family history or recurrent episodes
of bleeding [28]. In all HHT cases a history concerning
neurological symptoms were taken and screening for
PAVM was offered in order to perform embolization if
necessary. Screening for CAVM was only offered if the pa-
tient had experienced neurological symptoms or deficits.
Screening for HAVM was not performed routinely. In all
HHT families genetic counselling and mutation diagnos-
tics were offered. The controls were not clinical evaluated,
but only identified in a register search, having the same
age and sex as the included HHT patients and being alive
and having address in the County of Fyn 1.1.1995.
Mutation analysis
Genomic DNA was isolated from peripheral leukocytes.
All exons and exon-intron boundaries of ENG (RefSeq:
NM_001114753.1), ACVRL1 (RefSeq: NM_000020.2),
and SMAD4 (RefSeq: NM_005359.5) were analysed by
bi-directional sequencing and Multiplex Ligation-
dependent Probe Amplification (MLPA) analysis, as
described previously [12]. Before 2007, our laboratory
performed DGGE (denaturing gradient gel electrophor-
esis) and DHPLC (Denaturing High Pressure Liquid
Chromatography) analysis of ENG and ACVRL1, with
sequencing of relevant exons as described in detail in
other papers [8, 32]. All samples, without an identified
pathogenic mutation by this approach, were re-evaluated
in 2010–2012 with Sanger sequencing and MLPA ana-
lyses of the three HHT causative genes [12]. None of the
patients had mutations in SMAD4.
Danish population registries as data sources
Denmark has an array of nationwide registries which are
continuously updated and provide excellent opportunities
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for register-based research. Danish nationwide registries
can be accurately linked at the individual level using the
unique civil registration numbers assigned to all Danish
residents at birth or upon immigration [33]. Furthermore,
the highly organized structure of the tax-supported Da-
nish Health Service [34], which provides free of charge
health care to all citizens of the country regardless of in-
come, provides a favorable setting for the type of studies
included in this paper. To conduct the studies presented
in this manuscript we collected data from four nationwide
registries, all containing prospectively collected data.
The Danish Civil Registration System (Person Registry)
was established in 1968 and contains continuously updated
information on vital status, migration and residency. The
registry is based on the civil registration number [33]. Data
in this registry was updated in the full research period.
The Danish Cancer Registry (Cancer Registry) was
founded in 1942. It is mandatory to report incident cases
of cancer and selected tumors to the Cancer Registry.
Cancer diagnoses are recorded according to the Inter-
national Classification of Diseases, version 10 (ICD-10)
[35]. We used data from this registry updated until 1
January 2013.
The Danish Register of Causes of Death covers all
deaths among citizens dying in Denmark since 1875.
The register is computerized and it includes all the diag-
noses recorded at the death certificate as the evaluated
cause of death. Since 1994 only diagnoses according to
ICD-10 classification have been used [36]. We used data
from this registry updated until 1 January 2014.
The Danish Patient Registry includes information
on all procedures and treatments, together with all
associated diagnoses, for all admissions and outpatient
contacts (including visit to emergency rooms) man-
aged at Danish hospitals (public as well as private).
We used data from this registry updated as of 31
December 2014.
Statistics
We conducted survival analysis with follow-up as
time scale. Kaplan-Meier curves with 95% confidence
bands were calculated for HHT cases versus controls.
We used the same populations which were evaluated
for 90-month mortality [8]. Furthermore, hazard
ratios between cases and controls and between sub-
types were estimated with Cox regression, adjusting
for sex and age at start of follow-up and checking
fulfillment of the proportional hazards assumption.
Using knowledge of cancer diagnosis we also per-
formed Kaplan-Meier survival curves regarding cancer-
free survival. Concerning causes of death we used descrip-
tive statistics comparing causes of death in the group of
HHT patients and controls.
Results
All 73 HHT patients were followed for 20 years, as well
as 218 of 219 controls (one control was lost due to regis-
tration failure). Phenotype and genotype characteristics
of the HHT patients are shown in Table 1.
Crude survival showed that 41 (56%) HHT patients
and 121 (56%) controls survived the study period.
Survival curves are shown in (Fig. 2 a–e). We expected
to identify a higher mortality among HHT patients than
among controls, but there was no significant increased
mortality, and the curves evened out during the full fol-
low-up period. Neither a logrank test (p = 0.10) nor a
Cox regression adjusting for age and sex (HR = 1.27,
p = 0.24) found any significant differences in survival
between cases and controls. Subdividing according to
the genetic HHT subtype (Fig. 2b and c) did not reveal in-
creased mortality among either HHT1 or HHT2 patients
and neither a logrank test (p = 0.17) nor Cox regression
adjusted for age and sex (HR = 0.46, p = 0.066) found any
significant differences in survival between HHT1 and
HHT2. Subdividing according to sex (Fig. 2d and e) did
not reveal increased mortality in either sex. The number
of patients with cancer was too small to make any signifi-
cant change in the survival curves (cancer survival curves
not shown).
According to the Danish Patient Registry only 4 (5.5%)
of HHT patients were diagnosed with cancer during the
study period compared to 38 (17.4%) of the controls (p
= 0.012 using Fisher’s exact test). These results were vali-
dated using the Cancer Registry. Here we found the
same 4 HHT patients with a cancer diagnosis but we
only identified 32 of the 38 controls diagnosed with
Table 1 Pheno- and genotype distribution among HHT patients
All HHT
patients
Male Female
Number 73 34 39
Age 1 January 1995 (range) 53.8
(14–88)
51.5
(18–88)
55.5
(14–87)
PAVM diagnosed at CT or
Pulmonary angiography
23 9 14
HHT1 38 18 20
HHT2 24 14 10
JP-HHT 0 0 0
Unknown type 11 2 9
Died in the follow-up period 32 13 19
HHT stated as cause of death 6 3 3
Cancer stated as cause of death 3 1 2
Other HHT related diagnosis
stated as cause of death
10 6 4
Abbreviations: PAVM Pulmonary arteriovenous malformations, HHT1 Hereditary
Hemorrhagic Telangiectasia type 1, HHT2 Hereditary Hemorrhagic
Telangiectasia type 2, HHT- JP Hereditary Hemorrhagic Telangiectasia and
Juvenile Polyposis
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cancer (14.6%). The difference in cancer prevalence be-
tween HHT patients and controls was still significant (p
= 0.04 using Fisher’s exact test).
Discussion
In this study we were able to include all HHT patients
from a well-defined geographical area. Patients were in-
cluded regardless of severity of disease as long as they
fulfilled the diagnostic criteria of HHT. Even though
this was done before the Curacao criteria were estab-
lished, subsequent evaluation has demonstrated that all
patients fulfilled the Curacao criteria [21]. The problem
with referral bias was reduced substantially as HHT
cases with few symptoms, diagnosed through screening
of first degree relatives, also were included. However
subclinical cases of HHT may have been missed for in-
clusion in the case group. A well-defined control group
was identified using sex, birthday and County of Fyn
address as matching. The control group was not clinical
examined, and although the extremely low prevalence
of HHT makes it very unlikely, subclinical cases of
HHT in the control group cannot fully be excluded. In
this respect it should be noted that during the 20 years
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follow-up period no diagnosis of HHT was registered in
the control group.
The possibility of particular associations between can-
cer and HHT still needs further investigation. There is a
risk of confounding in the present study. We lack infor-
mation on smoking habits as well as lifestyle factors in
both patients and controls, and it is possible that HHT
patients due to their chronic disease adapt to a healthier
life style in order to cope better with their HHT. The
majority of cancer cases among controls were pulmon-
ary, making possible differences in smoking habits of
outmost importance. The explanation for difference in
number of cancer cases among controls using the
patient registry versus the cancer registry, is that the
cancer registry was not updated in the period of 2013–15.
A recent study [25] indicated that the incidence of cancer
is the same in HHT patients compared to the background
population although the same authors previously have
found a better survival of cancer among HHT patients
compared to controls. We speculate, as others [24],
whether these important results reflect a change in the ex-
pression of genes belonging to the TGF-β pathway influen-
cing angiogenesis which may reduce the risk of cancer
and/or increase survival of cancer. Our results support this,
but further studies of the angiogenesis among HHT pa-
tients are needed before we can reach a firm conclusion.
We have previously reported a slightly increased mor-
tality among HHT patients in the County of Fyn1974-95
[1]. We further did observe a slight trend towards in-
creased mortality in the County of Fyn 1995–2002 in
the current study group after 90 months’ observation.
With extended observation period the difference be-
tween HHT patients and controls disappeared. This may
be a random effect but it may also be a beneficial conse-
quence of the establishment of the HHT center. Al-
though we have included all HHT patients in a
geographical area independent of severity of disease, and
thereby have tried to reduce selection bias, we cannot
fully exclude that there may have been some young
HHT patients dying of complication to the disease be-
fore they were diagnosed with HHT. Nevertheless, we
did ask for information on siblings and children, when
the HHT patients were included, and we have no
suspicion that dying young has been common in the
families. To fully omit the risk of selection bias, all new-
borns of HHT parents should be genetic tested and
followed for a lifetime, comparing survival of siblings
with and without HHT. This is, however, not realistic
and we believe the present study gives the most
current and relevant information for HHT patients
and care takers on HHT survival. An explanation for
the survival curves that evens out could be that the
HHT patients may be protected against some of the
diseases related to older age, e.g. cancer and heart
disease, but this is speculative and may also be
blurred by lifestyle differences.
Other authors have reported increased mortality
among HHT patients. de Gussem et al. [7] reported a re-
duced life expectancy in a largely unscreened and un-
treated population of HHT patient (parents of HHT
patients). Donaldsen et al. [5] in their register study
identified a substantial risk of serious neurological and
hemorrhagic complications and an increased mortality,
using register data on patients registered with the HHT
diagnosis at the GP in UK, thus excluding subclinical
HHT cases without need of medical care. Further infor-
mation on the degree of surveillance of HHT complica-
tions and the way of managing the HHT disease is not
provided. Consequently, selection bias is likely as also
stated by the authors [27]. Our population was ascer-
tained using family investigations implying that all cases
regardless of severity and need of medical care were
identified and included. As expected for an autosomal
dominant trait we found equal prevalence in men and
woman, hence eliminating gender-related bias. All HHT
patients underwent clinical examination by the same in-
vestigator when included in the study. Furthermore, all
patients were informed about HHT and bleedings. Most
importantly, the HHT- patients were offered screening
and direct access to treatment for the most dangerous
complication (PAVM) at the Odense University Hospital.
When indicated the patients were also offered treatment
for other individual manifestations, including laser ther-
apy of the nose, iron treatment, endoscopic treatment of
the GI tract, embolization of PAVM, prophylactic antibi-
otics, and blood transfusion. Taken together, this is as-
sumed to reduce the risk of severe complications such
as: cerebral abscess, severe bleeding, stroke, TIA and
other HHT related complications.
Conclusion
We have enrolled HHT patients at an HHT-center
with highly skilled researchers and specialized treat-
ment modalities. Among the 73 HHT patients who
were followed for 20 years there was no increased
mortality. This may be partly due to screening for
and treatment of PAVMs, as well as information on
and treatment of other HHT manifestations (epistaxis
and GI-bleeding) at a dedicated HHT-center. Our
data also suggests that the benefit of having HHT
might be a reduced prevalence of cancer.
Additional files
Additional file 1: Table S2. Online only. Grouping of ICD-10 classification
according to HHT relevance Overview for details see Additional file 2:
Table S3. online only. (DOCX 14 kb)
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(DOCX 114 kb)
Abbreviation
ACVRL1: Activin A receptor type II-like 1; CA: Cerebral abscess;
CAVM: Cerebral arteriovenous malformations; ENG: Endoglin; GI: Gastro
intestinal; HAVM: Hepatic arteriovenous malformations; HHT: Hereditary
hemorrhagic telangiectasia; JP-HHT: Juvenile polyposis syndrome and HHT;
MLPA: Multiplex Ligation-dependent Probe Amplification; PAVM: Pulmonary
arteriovenous malformations
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